4//SEC Filing
Thompson Peter A. 4
Accession 0000947871-25-000360
CIK 0001710072other
Filed
Apr 3, 8:00 PM ET
Accepted
Apr 4, 7:42 PM ET
Size
8.8 KB
Accession
0000947871-25-000360
Insider Transaction Report
Form 4
Thompson Peter A
Director10% Owner
Transactions
- Purchase
Common Stock
2025-04-03$20.13/sh+372,578$7,499,995→ 14,809,075 total(indirect: See footnotes) - Purchase
Common Stock
2025-04-03$20.13/sh+124,193$2,500,005→ 443,792 total(indirect: See footnotes)
Footnotes (4)
- [F1]These shares of the Issuer's common stock were purchased in an underwritten public offering.
- [F2]These securities are held of record by OrbiMed Private Investments VI, LP ("OPI VI"). OrbiMed Capital GP VI LLC ("GP VI") is the general partner of OPI VI, and OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP VI. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI VI. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OPI VI.
- [F3]These securities are held of record by OrbiMed Genesis Master Fund, L.P. ("Genesis Master Fund"). OrbiMed Genesis GP LLC ("Genesis GP") is the general partner of Genesis Master Fund and OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by Genesis Master Fund. OrbiMed Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by Genesis Master Fund.
- [F4]Each of the Reporting Person, OrbiMed Advisors, GP VI, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.
Documents
Issuer
Edgewise Therapeutics, Inc.
CIK 0001710072
Entity typeother
Related Parties
1- filerCIK 0001357522
Filing Metadata
- Form type
- 4
- Filed
- Apr 3, 8:00 PM ET
- Accepted
- Apr 4, 7:42 PM ET
- Size
- 8.8 KB